News >

Vemurafenib/Rituximab Combo Reaches 100% CR Rate in Hairy Cell Leukemia

Angelica Welch
Published: Tuesday, Feb 06, 2018

Enrico Tiacci, MD

Enrico Tiacci, MD
The combination of vemurafenib (Zelboraf) and rituximab (Rituxan) in patients with relapsed/refractory hairy cell leukemia was proven to be safe and non-myelotoxic, producing durable and deep responses that in turn could provide an effective chemotherapy-free option in this heavily pretreated population, according to findings of a study presented during the 2017 ASH Annual Meeting.

Complete responses (CRs) were achieved in all 27 patients evaluable for efficacy, which included 2 patients who had incomplete platelet recovery.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication